An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Pfizer is licensing a promising investigational cancer medicine from a smaller company. This move improves the drugmaker's ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

The US’s policy under the Second Donald Trump Administration has undergone major changes, with experts saying that America is ...

Pfizer has struck a massive $1.25 billion deal with China’s 3SBio to license a promising cancer drug, beefing up its oncology ...

Bispecific anti-PD1/VEGF remains one of the hottest topics in the oncology field. Click here for a detailed analysis.

At the heart of the deal is an anti-Claudin18.2 antibody-drug conjugate being developed for solid tumors, including gastric ...

The U.S. Centers for Disease Control and Prevention is still recommending COVID-19 vaccines for healthy children, according to its latest published immunization schedule. A federal appeals court ...